Celsion Corporation to Participate in the Virtual 33ʳᵈ Annual Roth Conference

Rhea-AI Summary

Celsion Corporation (NASDAQ: CLSN) will engage in one-on-one meetings with investors during the Virtual 33rd Annual Roth Conference from March 15-17, 2021. A pre-recorded webcast of their presentation will be available on their website prior to the event. Interested investors are encouraged to contact their Roth Capital Partners sales representative for meeting arrangements. Celsion specializes in innovative cancer treatments, focusing on DNA-based immunotherapy and next-generation vaccines, with key products including GEN-1 for ovarian cancer and ThermoDox® for various cancer indications.

LAWRENCEVILLE, N.J., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will be holding one-on-one meetings with investors during the Virtual 33^rd Annual Roth Conference, being held March 15 – 17, 2021. A webcast of Celsion’s presentation will be pre-recorded and will be available on the Company’s website during the week before the conference.

Institutional and other investors interested in meeting with Celsion during the conference should contact their Roth Capital Partners sales representative or LHA Investor Relations. Conference information is available at www.roth.com/oc2021virtual.

About Celsion Corporation

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies, DNA-based therapies and directed chemotherapies through clinical trials and eventual commercialization. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox^®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit www.celsion.com.

Celsion Investor Contact
Jeffrey W. Church
Executive Vice President and CFO
609-482-2455
jchurch@celsion.com

LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

# # #

FAQ

What is the date of Celsion's participation in the Roth Conference?

Celsion will participate in the Virtual 33rd Annual Roth Conference from March 15-17, 2021.

How can investors arrange meetings with Celsion during the conference?

Investors should contact their Roth Capital Partners sales representative to arrange one-on-one meetings with Celsion.

Where can I find Celsion's presentation for the Roth Conference?

A pre-recorded webcast of Celsion's presentation will be available on their website prior to the conference.

What therapies is Celsion Corporation focused on?

Celsion focuses on DNA-based immunotherapy and next-generation vaccines for cancer treatment.

What is GEN-1 used for by Celsion?

GEN-1 is a DNA-based immunotherapy developed by Celsion for the localized treatment of ovarian cancer.